Skip to content

Cabozantinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: cabometyx, cabozantinib (S)-malate, cabozantinib malate, cabozantinib S-malate, cometriq, XL184

OnpEMA approvedFDA approvedPMDA approvedOrphan designationATC L01EX07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cabozantinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Protein Kinase Inhibitors. DrugCentral lists 34 molecular targets, including KDR, MERTK and SLTM. Recorded indications include Liver cell carcinoma, Medullary thyroid carcinoma, Metastatic renal cell carcinoma and Renal cell carcinoma.

  • Approval status: onp (first approved 2012 by the FDA).
  • Drug class: Kinase Inhibitor.
  • Mechanism of action: Protein Kinase Inhibitors.
  • Molecular targets: KDR, MERTK, SLTM and MET (34 listed in DrugCentral).
  • Indications: Liver cell carcinoma, Medullary thyroid carcinoma, Metastatic renal cell carcinoma and Renal cell carcinoma.
  • ATC code: L01EX07 (Other protein kinase inhibitors).
  • Molecular formula: C28H24FN3O5; molecular weight 501.51 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

  • Liver cell carcinoma
  • Medullary thyroid carcinoma
  • Metastatic renal cell carcinoma
  • Renal cell carcinoma

Mechanism & targets

Mechanism of action (MoA)Protein Kinase Inhibitors
Established pharmacologic classKinase Inhibitor

Molecular targets (34)

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2020-03-25PMDA—Takeda Pharmaceutical Company Limited
2014-03-21EMA—TMC Pharma Services LtdYes
2012-11-29FDA—EXELIXISYes

ATC classification

ATC codeTherapeutic hierarchy
L01EX07ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • FDA label: RET

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Palmar-plantar erythrodysaesthesia syndrome6254.6
Malignant neoplasm progression4111.4
Hepatic function abnormal2111.2
Diarrhoea1998.1
Off label use1635.1
Hypothyroidism1558.1
Decreased appetite1222.2
Proteinuria956.8
Hypertension768.9
Taste disorder747.5
Stomatitis602.1
Hair colour changes601.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cabozantinib is on its molecule page.

Molecular formulaC28H24FN3O5
Molecular weight501.51 g/mol
CAS number849217-68-1
InChIKeyONIQOQHATWINJY-UHFFFAOYSA-N
PubChem CID25102847
COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cabozantinib used for?

DrugCentral lists the following indications for Cabozantinib: Liver cell carcinoma, Medullary thyroid carcinoma, Metastatic renal cell carcinoma and Renal cell carcinoma.

How does Cabozantinib work?

Cabozantinib is classified as Protein Kinase Inhibitors; its molecular targets in DrugCentral include KDR (inhibitor), MERTK, SLTM and MET (inhibitor).

When was Cabozantinib first approved?

Cabozantinib was first approved by the FDA in 2012.

What drug class does Cabozantinib belong to?

Cabozantinib is in the Kinase Inhibitor class.

What is the chemical formula of Cabozantinib?

Cabozantinib has the molecular formula C28H24FN3O5 and a molecular weight of 501.51 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2012-11-29
AgencyFDA
Targets34
Indications4
FormulaC28H24FN3O5
DrugCentral ID4715
Interactive profile